Biologic infusion and drug claims, prior authorization and step therapy, joint injections, referral marketing and a claims portal for rheumatology practices, built on CMS rules and your payers' own policies.
Quick answer
Rheumatology billing services manage the claims a rheumatology practice creates: biologic infusions billed with the right drug code, units, NDC and JW or JZ modifier, drug prior authorizations and step therapy, joint injections, same-day visits and DXA scans. RCM Finder pairs that billing with front-desk assistants, referral marketing and a claims portal, starting with a free practice audit.
Rheumatology billing is different because much of the revenue runs through drugs. When a practice buys and infuses a biologic, the claim must match the drug code, units, NDC and waste modifier to the vial used. One mismatch can hold up the costliest line.
Medicare pays most Part B drugs at 106% of average sales price (ASP) under 42 CFR 414.904, and pays separately for giving the drug, per MedPAC (2024). A biosimilar is paid at its own ASP plus 6% of the reference product's ASP (8% for qualifying biosimilars during a five-year period). CMS updates ASP payment limits quarterly.
Each biosimilar has its own code. J1745 covers infliximab but excludes biosimilars, while Inflectra (infliximab-dyyb) is billed with Q5103. A switch changes the code, the NDC and often the authorization.
Each Medicare contractor lists drugs it considers usually self-administered, and those are excluded from Part B when given in the office. CGS's list (A52527) includes adalimumab (J0139), etanercept (J1438) and subcutaneous abatacept, and requires a JA (intravenous) or JB (subcutaneous) modifier where one code covers both routes. For covered office injections, see our 96372 injection billing guide.
In buy-and-bill, the practice buys the drug and bills the medical benefit. In white bagging, a specialty pharmacy ships the drug to the practice for one patient and bills the pharmacy benefit. In brown bagging, the patient brings the drug in. In both bagging models, the practice bills only for giving the drug, as a Mass General Brigham Health Plan explainer describes.
Some states, including Louisiana, Vermont and Virginia, limit or set standards for white bagging, per Triage Cancer's state-law chart (updated January 2024). The right model depends on your payer mix, cash flow and state rules.
We build our billing pipeline around how claims actually move through a practice: registration, charge entry, submission, payment and follow-up. For rheumatology, we add the drug, infusion and injection checks described on this page.
A rheumatology practice needs referrals, approved drugs, clean drug claims and software that shows every claim. Each pillar handles one.
Revenue leaks at the handoffs: an infusion booked before step-therapy history is sent, an unnoticed biosimilar switch, a missing waste line. We run all four pillars on one set of payer rules.
Our healthcare digital marketing builds demand from referring primary care offices and local patients searching for help with arthritis, gout, lupus or osteoporosis, through local SEO, Google Ads and reputation work.
Our virtual medical assistants for rheumatology work on your practice's time zone. They confirm the benefit for each biologic, start prior authorizations and track re-authorization dates.
Our end-to-end rheumatology revenue cycle management covers coding support, claim scrubbing, denial management and A/R follow-up, with extra checks on every drug and administration line.
Our practice management system tracks every claim by stage, applies specialty-aware billing logic per claim, checks data completeness before submission and flags payments below the expected amount.
Find where your infusion claims leak
We review recent infusion, injection and DXA claims, denial reasons and authorization logs, then show what to fix first. Pricing is quoted after the audit.
Most rheumatology claim problems trace to a few rules, mapped below. Codes are in our own words (the AMA owns CPT descriptors); check current code sets and your contractor's articles before billing.
| Service | Code examples (our wording) | Billing rule | Where claims break |
|---|---|---|---|
| IV infusion of a biologic | 96365, 96366 (first and added hours); 96413, 96415 (complex biologics) | One initial code per encounter, set by the main reason; chemotherapy-level codes can apply to monoclonal antibodies | Second initial code in one encounter without a two-IV-site protocol |
| Infused drug | J1745 (infliximab, per 10 mg); J0129 (abatacept, per 10 mg); J3262 (tocilizumab, per 1 mg) | Units from dose and billing unit; JZ if none discarded, JW line if some is | No JW or JZ on a single-dose drug; claim may be returned |
| Biosimilar | Q5103 (infliximab-dyyb, per 10 mg); J1745 excludes biosimilars | Bill the product given; its own code and NDC | Reference code still billed after a switch |
| Subcutaneous biologic in the office | J0139 (adalimumab); J1438 (etanercept) | On contractor self-administered lists; JA or JB on shared-route codes (CGS) | Billed to Part B and denied as a benefit exclusion |
| Joint aspiration or injection | 20600/20604 (small), 20605/20606 (intermediate), 20610/20611 (major); second of each pair adds ultrasound | One unit per joint, even with nearby bursae; no separate ultrasound guidance code | Separate ultrasound code; two units for one joint |
| Same-day visit | E/M with modifier 25; G2211 add-on | Only if significant and separately identifiable; 99211 not paid with infusion or chemotherapy administration codes | 25 when the only decision was to inject; G2211 on a 25 visit |
| DXA bone density | 77080 (DXA of the trunk bones); 77085 (adds vertebral fracture assessment) | Practitioner order; generally once per 23 months | Early repeat without a covered reason; two axial studies in one day |
Sources: CMS Medicare Claims Processing Manual ch. 12, sections 30.5 and 30.6.6 (chapter rev. May 2026); CMS JW/JZ modifier FAQ (undated; cites CY 2026 rules) and Transmittal 12067 (June 2023); Medicare Coverage Database article A52527 (CGS, version effective 10/08/2026); 2026 NCCI Policy Manual ch. 4 and ch. 9; CMS MLN907166 (2025); MLN Matters MM13473 (2025); 42 CFR 410.31; AAPC code summaries. Rules vary by contractor and payer.
The Medicare Claims Processing Manual (chapter 12, section 30.5) allows one initial infusion or injection code per encounter unless the protocol requires two IV sites, and the initial code reflects the main reason for the visit. Fluid used only to give a drug is not paid separately. Chemotherapy administration codes can apply to monoclonal antibodies, though contractors weigh more than the drug name. Medicare does not pay 99211 with an infusion or chemotherapy administration code.
In its CY 2026 fee schedule final rule, CMS permanently allowed virtual direct supervision (real-time audio and video) for incident-to services other than those with 10- or 90-day global periods. See also our oncology billing services page and our home infusion and IVIG billing guide.
CMS's JW and JZ modifier FAQ covers separately payable single-dose drugs, including those a physician office bills. The FAQ is undated, but the current version cites the CY 2026 rules. JW puts the discarded amount on its own line. JZ attests that nothing was discarded and has been required on applicable claims since July 1, 2023, per CMS Transmittal 12067 (June 2023). The FAQ says claims without correct modifiers on or after October 1, 2023 may be returned. Neither applies to multi-dose vials. Our J-code billing guide covers the code set itself.
Under 42 CFR 447.520, state Medicaid programs must require NDCs on physician-administered drug claims to collect rebates. The NUCC 1500 instructions (July 2025) place the N4 qualifier, the NDC without hyphens, a unit qualifier such as ME, ML or UN, and the quantity in the shaded area of item 24. Confirm each payer's rules.
Joint injection codes come in pairs by joint size; the second of each pair includes ultrasound guidance with a permanent recording and report. The 2026 NCCI policy manual bars a separate guidance code when the procedure code includes guidance, and allows one unit per joint even when nearby bursae are injected. For knee injections, see our orthopedic billing services page.
CMS's global surgery booklet (December 2025) includes a same-day visit in a 0-day minor procedure unless it is significant and separately identifiable, billed with modifier 25. NCCI adds that the decision to do the procedure is part of it. A different diagnosis is not required, per the claims manual. Under MLN Matters MM13473, G2211 is not paid on a modifier 25 visit unless the other service is a Part B preventive service, a vaccine administration or an annual wellness visit. See modifiers 25 vs 59.
Under 42 CFR 410.31, Medicare covers bone mass measurement for five groups, including people receiving, or expected to receive, glucocorticoids equal to 5 mg of prednisone or more a day for over three months. The treating practitioner orders it. Coverage is generally once every 23 months, more often when medically necessary, and scans that monitor an osteoporosis drug must use axial DXA. The NCCI radiology chapter allows one axial study per date. For denosumab (J0897), Wellpoint article A52399 requires documented calcium and vitamin D supplementation; other contractors may differ.
Clear the drug before the infusion is booked: confirm the benefit, send the step-therapy history and log the payer's deadline. Medicare Advantage deadlines are shorter for Part B drugs than for services.
Under 42 CFR 422.568 and 422.572, a Medicare Advantage plan must decide a standard Part B drug request within 72 hours and an expedited one within 24 hours, with no extension. The CMS-0057-F rule set 7-day standard and 72-hour expedited prior authorization deadlines from January 1, 2026, but those requirements exclude drugs.
Medicare Advantage plans may also use step therapy for Part B drugs. 42 CFR 422.136 limits it to new administrations, judged with a lookback of at least 365 days, and requires approval by a pharmacy and therapeutics committee. Send the past year's drug history with the first request.
Appeals pay off. In KFF's January 2026 analysis, Medicare Advantage insurers fully or partly denied 7.7% of 52.8 million prior authorization requests in 2024. Only 11.5% of denials were appealed, and 80.7% of appeals were partly or fully overturned. In the AMA's 2025 survey (published May 2026), physicians averaged 40 prior authorizations and 13 hours of staff and physician time weekly.
| Rule | Source | What the VMA checks before booking |
|---|---|---|
| Drugs on a contractor's self-administered list are excluded from Part B in the office | CGS A52527 (2026); other MACs publish their own | Medical or pharmacy benefit; specialty pharmacy route if self-injected |
| MA plans decide Part B drug requests in 72 hours, or 24 if expedited, with no extension | 42 CFR 422.568 and 422.572 | Request time logged; follow-up when the deadline passes |
| MA step therapy for Part B drugs: new administrations only, 365-day minimum lookback | 42 CFR 422.136 | Past year's drug history sent with the first request |
| CMS-0057-F's 72-hour and 7-day deadlines exclude drugs | CMS-0057-F fact sheet (2024) | Drug and service requests tracked on separate clocks |
| Medicaid requires NDCs on physician-administered drug claims | 42 CFR 447.520 | NDC of the stocked vial captured |
| Off-label rituximab: document failed prior treatments; re-treatment needs a documented response | CGS A58582 (2026) | Treatment and response notes on file before a new course |
| DXA generally once per 23 months unless medically necessary | 42 CFR 410.31 | Last DXA date; reason for any early repeat |
Sources: Medicare Coverage Database articles A52527 (CGS, version effective 10/08/2026) and A58582 (CGS, version effective 09/03/2026); eCFR 42 CFR 422.568, 422.572, 422.136, 447.520 and 410.31 (current October 2026); CMS-0057-F fact sheet (2024). Always check the member's current plan.
For the general workflow, see our prior authorization guide for providers and our tips to expedite prior authorization for medications.
See what slow approvals and denied drug lines cost you
Enter your claim volume and denial rate to estimate what your practice is losing, then bring the numbers to your audit.
Rheumatology growth starts with primary care referrals, then local search for conditions such as rheumatoid arthritis, gout, lupus and osteoporosis. Tracking must respect HIPAA.
We build location and condition pages and a simple referral path for primary care offices. Review responses never confirm someone is a patient.
HHS guidance on online tracking says tracking on appointment pages may collect protected health information, the vendor then needs a Business Associate Agreement, and a cookie banner is not a HIPAA authorization. A June 2024 court order vacated part of that guidance; we still keep tracking off forms unless the vendor signs a BAA.
Stay in-house if you have experienced infusion coders and front-desk time for drug authorizations. Use a billing-only vendor if claims are your only gap. Choose a combined partner when problems start before the claim.
| Job | In-house team | Billing-only vendor | Four-pillar partner (RCM Finder) |
|---|---|---|---|
| Benefit check and drug prior authorization | Front desk, between calls | Usually left to the practice | VMA checks the benefit and tracks the request |
| Drug units, NDC and JW or JZ | Depends on one biller | Fixed on the claim, after the fact | Matched to the infusion record before submission |
| Biosimilar switches | Found at the first denial | Updated when the practice reports it | Approval, code and NDC updated together |
| Same-day visit and injection coding | Provider habit | Coded as sent | Checked against the note before submission |
| Referral growth and reviews | A separate agency, or nobody | Not included | Marketing pillar tied to booked consults |
| Cost structure | Salaries, benefits, turnover | Varies; ask how fees are set | Quoted after a free practice audit |
If you need only one pillar, the audit will say so. Our revenue cycle management services and virtual medical assistant services can be contracted separately.
We start with a free audit and change nothing until you see the findings.
We review recent infusion, injection and DXA claims, denials and authorization logs against your infusion records.
We put a Business Associate Agreement in place before accessing patient data. Then we work inside your existing EHR (for example PrognoCIS, eClinicalWorks or athenahealth).
Your contractor's self-administered drug list and your plans' drug authorization and step-therapy rules become a checklist and portal workflow rules.
VMAs verify benefits and start drug authorizations. Claims are scrubbed, submitted and worked through denials and A/R.
Each week we review denials by reason, A/R days, infusions cleared in advance and drug lines paid below the expected amount.
Talk to us about your infusion suite
Tell us your drug mix, chair count and hardest payer. We will tell you honestly whether we fit.
Any billing vendor handling your patients' data is a HIPAA business associate. Get a Business Associate Agreement before any access, and check how access is limited and logged.
HHS guidance names billing and claims processing as business associate work; subcontractors need their own agreement. The minimum necessary standard limits use and disclosure to what each task needs. The Security Rule's technical safeguards require access control, audit controls, integrity controls, person or entity authentication and transmission security.
We use role-based access, audit logging and encrypted (HTTPS) connections, and we put a Business Associate Agreement in place before accessing patient data. For your side, use our HIPAA compliance checklist for medical practices.
We would rather tell you now than after you sign. Here is where we fit and where we do not.
A good fit if you are
Probably not a fit if you are
What we would do first if we were running your practice's revenue cycle tomorrow.
We match each drug line to the infusion record: product, NDC, dose given and amount discarded. Units and modifiers come from that record.
We confirm medical or pharmacy benefit, your contractor's self-administered drug list and any specialty pharmacy requirement first.
A switch changes the code, the NDC and often the authorization. We update all three before the next infusion.
Infusion codes are billed by the hour, so times must be clear. We also flag any day with two initial administration codes.
We check that the note shows work beyond the decision to inject, and we leave G2211 off those visits unless an exception applies.
In KFF's 2024 Medicare Advantage data, most appealed denials were overturned, yet few were appealed. We appeal with the order, drug history and infusion record.
They cover coding support, claim scrubbing, submission, denial management and A/R follow-up for rheumatology visits, infusions, joint injections and bone density scans. A good service also checks drug claims line by line: the code for the exact product, units, NDC and the JW or JZ modifier. RCM Finder adds front-desk assistants for drug authorizations, referral marketing and a claims portal, so one team owns the process from referral to payment.
Use them on separately payable drugs from single-dose containers. If part of the vial is discarded, bill the administered units on one line and the discarded units on a second line with JW. If nothing is discarded, add JZ to the drug line. CMS has required JZ since July 1, 2023, and says claims without correct modifiers on or after October 1, 2023 may be returned. Do not use either for multi-dose vials.
Only when the visit is significant and separately identifiable from the injection. Medicare treats the decision to do a minor procedure as part of it. When there is separate work, such as managing another condition, bill the visit with modifier 25 and document it. Medicare does not pay G2211 on a modifier 25 visit unless the other service is preventive care, a vaccine administration or an annual wellness visit.
It depends on the drug. Each Medicare contractor publishes a list of drugs it considers usually self-administered, and those are excluded from Part B when given in the office. CGS's list, for example, includes adalimumab, etanercept and subcutaneous abatacept. Infused drugs such as infliximab have their own Part B codes and are billed with an administration code. Check your contractor's list and the patient's pharmacy coverage before ordering.
For a Part B drug, a Medicare Advantage plan must decide a standard request within 72 hours and an expedited request within 24 hours, and it cannot extend either deadline. Plans may use step therapy for Part B drugs, but only for new administrations, with a lookback of at least 365 days. The 7-day deadline that started in 2026 applies to service requests, not drugs.
Generally once every 23 months for people in a covered group, such as estrogen-deficient women at clinical risk, people on long-term glucocorticoids, or people being monitored on an FDA-approved osteoporosis drug. More frequent scans can be covered when medically necessary, for example to monitor glucocorticoid therapy lasting more than three months or to confirm a baseline. The treating practitioner must order the scan, and scans that monitor an osteoporosis drug must use axial DXA.
Tell us about your practice. A member of our operations team replies within one business day.
Pricing is quoted after the audit, based on your volume and the services you choose. Prefer to talk? Call +1 (302) 556-2288.
Tell us about your practice
We use cookies to understand how our site is used and to measure our advertising. You can accept or reject non-essential cookies. See our Privacy Policy.
